Valbiotis SA (ALVAL.PA)
EUR 1.36
(-1.59%)
EUR 1.36
(-1.59%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 3.89 Million EUR | -10.47% |
| 2022 | 4.35 Million EUR | -5.35% |
| 2021 | 4.6 Million EUR | 32.03% |
| 2020 | 3.48 Million EUR | 109.63% |
| 2019 | 1.66 Million EUR | 6.54% |
| 2018 | 1.56 Million EUR | 0.06% |
| 2017 | 1.55 Million EUR | 100.9% |
| 2016 | 776 Thousand EUR | 1.97% |
| 2015 | 761 Thousand EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 Q2 | 4.38 Million EUR | 0.0% |
| 2023 Q4 | 4.77 Million EUR | 0.0% |
| 2023 FY | 3.89 Million EUR | -10.47% |
| 2022 FY | 4.35 Million EUR | -5.35% |
| 2022 Q2 | 4.33 Million EUR | 0.0% |
| 2022 Q4 | 4.35 Million EUR | 0.0% |
| 2021 FY | 4.6 Million EUR | 32.03% |
| 2021 Q4 | 4.6 Million EUR | 0.0% |
| 2021 Q2 | 5.28 Million EUR | 0.0% |
| 2020 Q4 | 3.48 Million EUR | 0.0% |
| 2020 Q2 | 1.64 Million EUR | 0.0% |
| 2020 FY | 3.48 Million EUR | 109.63% |
| 2019 Q2 | 1.59 Million EUR | 0.0% |
| 2019 Q4 | 1.66 Million EUR | 0.0% |
| 2019 FY | 1.66 Million EUR | 6.54% |
| 2018 FY | 1.56 Million EUR | 0.06% |
| 2018 Q4 | 1.56 Million EUR | 0.0% |
| 2018 Q2 | 1.46 Million EUR | 0.0% |
| 2017 Q2 | 1.11 Million EUR | 0.0% |
| 2017 Q4 | 1.55 Million EUR | 0.0% |
| 2017 FY | 1.55 Million EUR | 100.9% |
| 2016 Q4 | 776 Thousand EUR | 0.0% |
| 2016 FY | 776 Thousand EUR | 1.97% |
| 2015 FY | 761 Thousand EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 1.1 Million EUR | -254.042% |
| ABIVAX Société Anonyme | 44.69 Million EUR | 91.279% |
| Adocia SA | 4.54 Million EUR | 14.141% |
| Aelis Farma SA | 2.04 Million EUR | -90.332% |
| Biophytis S.A. | 3.11 Million EUR | -25.297% |
| Advicenne S.A. | 15.89 Million EUR | 75.478% |
| genOway Société anonyme | 5.51 Million EUR | 29.375% |
| IntegraGen SA | 642.28 Thousand EUR | -506.9% |
| Medesis Pharma S.A. | 1.2 Million EUR | -224.833% |
| Neovacs S.A. | 650 Thousand EUR | -499.692% |
| NFL Biosciences SA | 39.2 Thousand EUR | -9843.117% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 10.525% |
| Quantum Genomics Société Anonyme | 1.96 Million EUR | -98.844% |
| Sensorion SA | 1.24 Million EUR | -214.124% |
| Theranexus Société Anonyme | 2.46 Million EUR | -58.409% |
| TME Pharma N.V. | - EUR | -Infinity% |
| TheraVet SA | 1 Million EUR | -289.567% |
| Valerio Therapeutics Société anonyme | 6.9 Million EUR | 43.556% |
| argenx SE | 15.35 Million EUR | 74.612% |
| BioSenic S.A. | 15.57 Million EUR | 74.969% |
| Celyad Oncology SA | 902 Thousand EUR | -332.151% |
| DBV Technologies S.A. | 4.52 Million USD | 13.875% |
| Galapagos NV | 4.94 Million EUR | 21.157% |
| Genfit S.A. | 62.25 Million EUR | 93.738% |
| GeNeuro SA | 6.49 Million EUR | 39.96% |
| Hyloris Pharmaceuticals SA | 344 Thousand EUR | -1033.14% |
| Innate Pharma S.A. | 30.6 Million EUR | 87.264% |
| Inventiva S.A. | 25.61 Million EUR | 84.783% |
| MaaT Pharma SA | 5.42 Million EUR | 28.147% |
| MedinCell S.A. | 52.8 Million EUR | 92.617% |
| Nanobiotix S.A. | 41.66 Million EUR | 90.643% |
| Onward Medical N.V. | 16.3 Million EUR | 76.095% |
| Oryzon Genomics S.A. | 3.45 Million EUR | -12.965% |
| OSE Immunotherapeutics SA | 35.5 Million EUR | 89.022% |
| Oxurion NV | 117 Thousand EUR | -3231.624% |
| Pharming Group N.V. | 123.65 Million EUR | 96.848% |
| Poxel S.A. | 40.14 Million EUR | 90.29% |
| GenSight Biologics S.A. | 1.04 Million EUR | -271.947% |
| Transgene SA | 17 Thousand EUR | -22829.412% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 2.87 Billion EUR | 99.865% |
| Valneva SE | 132.76 Million EUR | 97.064% |
| Vivoryon Therapeutics N.V. | - EUR | -Infinity% |